EPS for Knight Therapeutics Inc. (GUD) Expected At $0.04

February 20, 2018 - By Louis Casey

 EPS for Knight Therapeutics Inc. (GUD) Expected At $0.04

Analysts expect Knight Therapeutics Inc. (TSE:GUD) to report $0.04 EPS on March, 15.They anticipate $0.02 EPS change or 33.33 % from last quarter’s $0.06 EPS. T_GUD’s profit would be $5.72 million giving it 48.25 P/E if the $0.04 EPS is correct. After having $0.03 EPS previously, Knight Therapeutics Inc.’s analysts see 33.33 % EPS growth. The stock increased 1.18% or $0.09 during the last trading session, reaching $7.72. About 94,780 shares traded. Knight Therapeutics Inc. (TSE:GUD) has 0.00% since February 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Knight Therapeutics Inc. (TSE:GUD) Ratings Coverage

Among 2 analysts covering Knight Therapeutics (TSE:GUD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Knight Therapeutics had 11 analyst reports since May 12, 2016 according to SRatingsIntel. TD Securities maintained it with “Buy” rating and $12.50 target in Friday, March 17 report.

Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The company has market cap of $1.10 billion. The company's commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement. It has a 61.76 P/E ratio. The Company’s products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation.

More notable recent Knight Therapeutics Inc. (TSE:GUD) news were published by: Seekingalpha.com which released: “Knight Therapeutics (KHTRF) CEO Jonathan Ross Goodman on Q2 2017 Results …” on August 10, 2017, also Seekingalpha.com with their article: “How Many Times Can Knight Therapeutics Issue Equity?” published on September 22, 2016, Marketwired.com published: “Knight Therapeutics and SIFI SpA Announce Filing of New Drug Submission for …” on February 15, 2018. More interesting news about Knight Therapeutics Inc. (TSE:GUD) were released by: Seekingalpha.com and their article: “Knight Therapeutics’ (KHTRF) Management on Q1 2017 Results – Earnings Call …” published on May 11, 2017 as well as Seekingalpha.com‘s news article titled: “Knight Therapeutics: The Outsider CEO You’ve Never Heard Of” with publication date: November 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: